DNM1L and metabolic dysfunction-associated steatohepatitis: The results of this study suggest that DRP1, an important therapeutic target in NASH pathology, may regulate abnormal mitochondrial function and morphology, ROS production, and increased oxidative stress leading to fat accumulation and fibrosis (Figure 6).